Pneumonia in patients with rheumatoid arthritis: effect of microbial airway colonization

Short title: Airway colonization and pneumonia in patients with rheumatoid arthritis

Shuhei Ideguchi^{1,2}, Kazuko Yamamoto^{2,3,4*}, Masahiro Tahara⁵, Tomohiro Koga⁶,
Shotaro Ide⁷, Tatsuro Hirayama², Takahiro Takazono², Yoshifumi Imamura², Taiga
Miyazaki², Noriho Sakamoto², Shimpei Morimoto⁸, Koichi Izumikawa³, Katsunori
Yanagihara⁹, Kazuto Ashizawa¹⁰, Takatoshi Aoki¹¹, Atsushi Kawakami⁶, Kazuhiro
Yatera⁵, Hiroshi Mukae^{1,2}

¹Department of Respiratory Medicine, Nagasaki University Graduate School of
Biomedical Sciences, Nagasaki, Japan

²Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan

³Department of Infection Control and Education Center, Nagasaki University Hospital,
Nagasaki, Japan

⁴Clinical Research Center, National Organization Hospital Nagasaki Medical Center,
Nagasaki, Japan

⁵Department of Respiratory Medicine, University of Occupational and Environmental
Health, Japan, Fukuoka, Japan

⁶Department of Immunology and Rheumatology, Division of Advanced Preventive
Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences,
Nagasaki, Japan

24 ⁷Department of Respiratory Medicine, Isahaya General Hospital, Nagasaki, Japan

25 ⁸Innovation Platform & Office for Precision Medicine, Nagasaki University Graduate

26 School of Biomedical Sciences, Nagasaki, Japan

27 ⁹Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan

28 ¹⁰Department of Clinical Oncology, Nagasaki University Graduate School of

29 Biomedical Sciences, Nagasaki, Japan

30 ¹¹Department of Radiology, University of Occupational and Environmental Health,

31 Japan, Fukuoka, Japan

32

33 *Corresponding author

34 E-mail: kazukomd@nagasaki-u.ac.jp (KY)

35

36

37 Abstract

38 Rheumatoid arthritis frequently complicates airway diseases and is associated
39 with high rates of pneumonia and mortality. The relationship between microorganisms
40 colonizing the lower respiratory tract and the subsequent incidence of pneumonia in
41 patients with rheumatoid arthritis is unclear. In this study, we aimed to identify
42 microorganisms colonizing the lower respiratory tract in patients with rheumatoid
43 arthritis related to the risk of developing subsequent pneumonia in these patients.

44 A retrospective cohort study was designed to include a total of 121 patients with
45 rheumatoid arthritis (median age, 67 years; women, 78.5%) who underwent
46 bronchoscopy at three hospitals from January 2008 to December 2017. The following
47 information was extracted from their electronic medical records: patient characteristics,
48 microorganisms detected by bronchoscopy, and subsequent incidences of pneumonia.
49 The patients were divided into groups based on the microorganisms isolated from the
50 lower respiratory tract and compared with control subjects. The cumulative incidence of
51 pneumonia was assessed using the Kaplan–Meier method and log-rank test. Risk factors
52 for pneumonia were analyzed using the Cox proportional-hazards analysis.

53 The most frequently isolated microbes from the lower respiratory tract in
54 descending order were *Pseudomonas aeruginosa*, *Staphylococcus aureus*, and
55 *Haemophilus influenzae*. The annual incidence rates of pneumonia per 1000 patients
56 were 100, 62, 132, and 38, in the *P. aeruginosa*, *S. aureus*, *H. influenzae*, and control
57 group, respectively. Patients colonized with *P. aeruginosa* had a higher frequency of
58 macrolide use and a higher degree of bronchiectasis than patients in the control group.
59 The rate of the subsequent incidence of pneumonia was higher in the *P. aeruginosa*

group ($P = 0.038$), and *P. aeruginosa* was an independent risk factor for pneumonia (hazard ratio, 3.504; 95% confidence interval, 1.153–10.330).

The colonization of the lower respiratory tract by *P. aeruginosa* in patients with rheumatoid arthritis was associated with the subsequent incidence of pneumonia.

Introduction

The high incidence of pneumonia and associated mortality in patients with rheumatoid arthritis (RA) is a critical concern [1]. Airway diseases (ADs) such as bronchiectasis are common complications of RA, with a rate of 10–30% [2, 3]; patients with RA and ADs have a significantly poor prognosis [4]. *Pseudomonas aeruginosa* increases the risk of mortality and exacerbation in patients with bronchiectasis [4, 5]; however, the relationship between airway colonization and the incidence of pneumonia in patients with RA has not yet been clarified. Thus, we aimed to identify whether colonization of the lower respiratory tract (LRT) by microorganisms, particularly *P. aeruginosa*, correlated with the occurrence of pneumonia in patients with RA.

Materials and methods

Patients and study design

This retrospective cohort study was conducted at the Nagasaki University Hospital, University of Occupational and Environmental Health, Japan, and Isahaya General Hospital, from January 2008 to December 2017. This multicenter study was conducted in compliance with the Declaration of Helsinki and was approved by the Ethics Committees of the participating institutions (Nagasaki University Hospital, Approval Number: 19061714; University of Occupational and Environmental Health,

82 Japan, Approval Number: 19-044; Isahaya General Hospital, Approval
83 Number: 2020-9). The requirement for patient consent was waived due to the
84 retrospective nature of the study, which ensured anonymity.

85 The inclusion criteria were as follows: age ≥ 20 years, an RA diagnosis by
86 rheumatologists certified by the Japan College of Rheumatology [6], and bronchoscopy
87 performed by a pulmonary physician. We excluded patients if they had active infections
88 requiring antimicrobial agents at the time of bronchoscopy; malignancy diagnosed
89 within five years of the study; tracheotomy; cystic fibrosis (CF); or at least one of the
90 following conditions: human immunodeficiency virus infection, a CD4 cell count
91 $< 350/\mu\text{L}$, solid organ transplantation, or neutropenia < 500 cells/ μL . Patient
92 characteristics and RA status were extracted from the hospital's electronic medical
93 records.

94 **Evaluation of bronchiectasis**

95 Chest computed tomography (CT) was performed before bronchoscopy.
96 Bronchiectasis was assessed by blinded reads, based on the modified Reiff score [4], by
97 two board-certified radiologists from the Japanese Radiological Society with an average
98 experience of 25 years. The Reiff score indicates the degree of bronchial
99 dilatation (tubular, 1; varicose, 2; and cystic, 3) and number of lobes involved. The
100 lingular segment was evaluated as an independent lobe. Scores ranged from 1 to 18, and
101 patients without bronchodilation were assigned a score of 0.

102 **Identification of the lower respiratory tract-colonizing** 103 **microbes**

104 To detect the colonizing microorganisms in the LRT, bronchial lavage or
105 intratracheal sputum collected by bronchoscopy was directly cultured using blood with
106 chocolate agar (37 °C, 5% CO₂), anero Columbia agar (anaerobic chamber), and bromo
107 thymol blue with chromagar (37 °C) for detecting gram-positive, gram-negative, and
108 anaerobic bacteria and fungi.

109 **Endpoint**

110 The data were censored on March 31, 2019. Pneumonia incidence and
111 pneumonia-free survival, calculated from the date of bronchoscopy to the date of
112 pneumonia diagnosis, were recorded. Patients who did not develop pneumonia or who
113 were lost to follow-up were censored at the date of last contact. Pneumonia was
114 confirmed by the presence of new lung infiltrates and at least one of the following acute
115 respiratory symptoms: cough, sputum production, dyspnea, a body temperature of
116 ≥ 38.0 °C, abnormal auscultatory findings, and leukocyte counts of >10000 cells/ μ L or
117 <4000 cells/ μ L.

118 **Statistical analysis**

119 The Mann–Whitney U test was used for analyzing continuous variables, and
120 Fisher’s exact test for categorical variables. The cumulative incidence of pneumonia
121 was estimated using the Kaplan–Meier method and log-rank test. Baseline variables
122 with a *P*-value <0.10 (by univariate analysis) and previously reported risk factors for
123 pneumonia in patients with RA were included in the multivariate analysis. The risk of
124 pneumonia was evaluated using Cox proportional-hazards models (CPHM) to
125 determine hazard ratios (HRs) with 95% confidence intervals (95% CIs). A *P*-value

126 <0.05 was considered statistically significant. Analyses were performed using
127 JMP[®] 13 (SAS Institute Inc., Cary, NC, USA).

128 **Results**

129 **Eligible patients**

130 Among the 228 patients with RA who underwent bronchoscopy during the
131 study period, 107 were excluded from the study, including 71 with active
132 infections (pneumonia, 43; non-tuberculosis mycobacteria, 16; cryptococcosis, 7;
133 aspergillosis, 3; *Pneumocystis*, 1; and other mycosis, 1); 33 with malignancies (lung, 28;
134 renal, esophageal, ovarian, endometrial, and adult T-cell leukemia-lymphoma; 1 each);
135 1 with a tracheotomy; and 1 with solid organ transplantation. No data were available for
136 1 patient who was also excluded. Consequently, 121 patients were included in the
137 study (Fig 1).

138 **Fig 1. Selection of eligible patients.** RA, rheumatoid arthritis

139 **Lower respiratory tract colonization by microbes**

140 The detected microbes in the LRT samples are listed in Table 1. The LRT
141 samples tested positive in 100 patients (82.6%), including 41 (33.9%) with normal oral
142 flora. Among the frequently isolated pathogens, *P. aeruginosa* (13.2%), *Staphylococcus*
143 *aureus* (12.4%), and *Haemophilus influenzae* (5.0%) were the most prominent. The
144 other pathogens were *Streptococcus pneumoniae* (1.7%), other streptococci (3.3%),
145 other gram-negative bacilli (5.0%), anaerobic bacteria (1.7%), nontuberculous
146 mycobacteria (4.1%), *Candida* species (3.3%), and other fungi (2.5%).

147 **Table 1. Microorganisms detected by bronchoscopy**

Organism	Number (%)
<i>Pseudomonas aeruginosa</i>	16 (13.2)
<i>Staphylococcus aureus</i>	15 (12.4)
<i>Haemophilus influenzae</i>	6 (5.0)
<i>Streptococcus pneumoniae</i>	2 (1.7)
Other streptococci	4 (3.3)
Anaerobic bacteria	2 (1.7)
<i>Candida</i> species	4 (3.3)
Other fungi	3 (2.5)
Other microbes ^a	11 (9.1)
Oral flora	41 (33.9)
Negative	21 (17.4)

148 ^a*Stenotrophomonas maltophilia*, *Burkholderia cepacia*, *Klebsiella oxytoca*,

149 *P. fluorescens*, *Serratia marcescens*, *Mycobacterium intracellulare*, and *M. gordonae*.

150 **Patient groups based on the lower respiratory tract-colonizing** 151 **microbes**

152 Patients with RA were divided into groups depending on the microorganisms
153 isolated from the LRT—*P. aeruginosa* (*Pa* group), *S. aureus* (*Sa* group), and
154 *H. influenzae* (*Hi* group). The others, including those whose samples tested
155 negative (n = 21) or positive for normal oral flora and other pathogens (n = 22), were
156 considered as the control group and were compared with the abovementioned bacteria
157 groups (Table 2).

Table 2. Characteristics of patients with RA, including those whose lower respiratory tract was colonized by each of the three major bacterial species

	Total (n = 121)	<i>Pseudomonas aeruginosa</i> (n = 16)	<i>Staphylococcus aureus</i> (n = 15)	<i>Haemophilus influenzae</i> (n = 6)	Control (n = 84)
Age (years)	67 (61–76)	66 (61–76)	63 (58–76)	69 (64–75)	68 (61–76)
Female patients, %	78.5	87.5	93.3	66.7	75.0
Performance status	1 (0–1)	* 0 (0–1)	1 (0–1)	1 (0–1)	1 (0–1)
Smoking (pack-year)	0 (0–0)	0 (0–0)	0 (0–0)	0 (0–43)	0 (0–2)
Duration of RA (years)	5.2 (0.6–15.6)	3.1 (0.5–8.7)	3.4 (0.1–11.1)	5.8 (1.9–19.7)	5.4 (0.6–16.1)
DAS28-ESR	4.8 (3.7–6.0)	5.4 (4.1–6.2)	4.6 (3.2–5.7)	4.4 (3.5–4.8)	5.1 (3.7–6.4)
MTX use, %	51.2	62.5	53.3	33.3	50.0
GC use, %	36.4	37.5	* 6.7	33.3	41.7
GC dosage [‡] , mg/day	0 (0–3)	0 (0–3)	* 0 (0–0)	0 (0–3)	0 (0–4)
Duration of GC use (months)	0 (0–22)	0 (0–41)	* 0 (0–0)	0 (0–44)	0 (0–27)
Biologics use, %	22.3	25.0	26.7	16.7	21.4
Macrolide use, %	14.9	* 43.8	26.7	0	8.3
DM, %	8.4	12.5	6.7	16.7	7.1
ILD, %	33.9	18.8	* 6.7	33.3	41.7
COPD, %	6.6	12.5	0	16.7	6.0
Modified Reiff score	2 (0–3)	* 6.5 (4–10.8)	* 6 (2–12)	1.5 (0.8–7.8)	4 (0.3–6)
Observation period	41 (18–68)	41 (20–86)	45 (6–68)	55 (22–92)	41 (20–65)

(months)

160 Data are presented as frequency (%) or median (interquartile range)

161 RA, rheumatoid arthritis; DM, diabetes mellitus; ILD, interstitial lung disease;

162 COPD, chronic obstructive pulmonary disease; MTX, methotrexate;

163 GC, glucocorticoid; DAS, disease activity score; ESR, erythrocyte sedimentation rate.

164 * $P < 0.05$ compared to the control group

165 ‡Prednisolone dosage

166 **Patient backgrounds per group (based on the lower**

167 **respiratory tract-colonizing microbes)**

168 The age, sex, smoking history, RA duration, and observation period were not

169 different among the groups. The incidence of diabetes mellitus (DM), chronic

170 obstructive pulmonary disease (COPD), and interstitial lung disease (ILD) was

171 relatively low in the *Sa* group. None of the patients in the *Sa* group used

172 glucocorticoids (GCs). Long-term macrolides (≥ 1 month) were more commonly

173 implemented in the *Pa* group. The *Pa* and *Sa* groups showed a significantly higher

174 degree of bronchiectasis, detected by the modified Reiff score.

175 **Incidence and hazard ratios of pneumonia**

176 The annual incidence rates of pneumonia per 1000 patients were 100, 62, 132,

177 and 38, in the *Pa*, *Sa*, *Hi*, and control groups, respectively. Kaplan–Meier curves are

178 shown in Fig 2. Log-rank tests revealed that the *Pa* group had a significantly higher

179 incidence of pneumonia ($P = 0.038$). The *Hi* group was not analyzed using CPHM since

180 no proportional hazard was established. *S. aureus* colonization was not a statistically

181 significant risk factor for subsequent pneumonia. To compare the *Pa* group with the

control group, the HRs were adjusted for age, sex, performance status, DM, ILD, COPD, GCs, and the modified Reiff score using CPHM. *P. aeruginosa* colonization was an independent risk factor for pneumonia in patients with RA (HR, 3.504; 95% CI, 1.153–10.330; Table 3).

Fig 2. Kaplan–Meier plots and number-at-risk tables for the probability of pneumonia-free survival. Control group: patients with microbes other than *Pseudomonas aeruginosa*, *Staphylococcus aureus*, and *Haemophilus influenzae*.

Table 3. Hazard ratios for pneumonia.

	Univariate analysis		Multivariate analysis	
	HR (95% CI)	P-value	HR (95% CI)	P-value
Age	1.039 (0.991–1.094)	0.119	0.999 (0.939–1.067)	0.971
Female sex	0.547 (0.203–1.726)	0.281	0.549 (0.139–2.385)	0.409
Smoking	1.007 (0.983–1.023)	0.526		
Performance status	1.468 (0.780–2.561)	0.222	1.354 (0.612–2.798)	0.431
DM	3.860 (0.873–12.228)	0.071	1.714 (0.307–7.951)	0.515
ILD	1.794 (0.721–4.527)	0.201	2.554 (0.831–8.169)	0.102
COPD	3.547 (0.815–10.929)	0.084	1.624 (0.304–7.647)	0.546
Duration of RA	1.022 (0.982–1.057)	0.264		
MTX	0.770 (0.308–1.951)	0.574		
GC use	1.564 (0.617–3.912)	0.338	1.319 (0.405–4.061)	0.636
Biologics	0.824 (0.234–2.284)	0.728		
Macrolide	0.799 (0.183–2.457)	0.719		

DAS28-ESR	0.946 (0.664–1.356)	0.760		
Modified Reiff score	1.106 (0.983–1.247)	0.093	1.135 (0.982–1.311)	0.084
<i>Pa</i> colonization	2.636 (0.965–6.727)	0.058	3.504 (1.153–10.330)	0.028

HR, hazard ratio; CI, confidence interval; ILD, interstitial lung disease; COPD, chronic obstructive pulmonary disease; RA, rheumatoid arthritis; MTX, methotrexate; GC, glucocorticoid; DAS, disease activity score; ESR, erythrocyte sedimentation rate; *Pa*, *Pseudomonas aeruginosa*

Discussion

We retrospectively analyzed pneumonia in patients with RA based on the microbes that colonized the LRT. *P. aeruginosa*, *S. aureus*, and *H. influenzae* were the most frequent colonizers, and *P. aeruginosa* colonization was an independent risk factor for subsequent pneumonia in patients with RA. The annual incidence rate of pneumonia per 1000 patients in these three groups was higher than that in the control group, while the frequency of pneumonia in the control group in this study was similar to the frequency in patients with RA in a previous study [7]. To the best of our knowledge, this is the first study that focuses on microbial colonization of the LRT as a risk factor for pneumonia in patients with RA. The strength of this study was the evaluation of microbes by bronchoscopy, minimizing oral bacterial contamination and reflecting LRT-specific flora. Another strength was the novel approach to evaluate whether colonized *P. aeruginosa* was directly correlated with subsequent pneumonia in patients with RA.

208 *P. aeruginosa* has been reported as one of the major causative
209 microorganisms of pneumonia in patients with RA [1]. The risks of pneumonia in the
210 *Pa* group may have been underestimated in this study due to frequent macrolide use in
211 older patients. Long-term macrolide treatment can reduce pulmonary exacerbation and
212 improve bronchiectasis in non-CF [8, 9]; moreover, macrolides possibly prevent
213 pneumonia in older adults [10]. A relatively higher prevalence of DM and high-degree
214 bronchiectasis in the *Pa* group may also have affected pneumonia incidences.

215 Conventional culture methods in non-CF patients with bronchiectasis tend to
216 under-recognize *H. influenzae*, compared to *P. aeruginosa* and *S. aureus* [11].
217 Therefore, the high incidence of pneumonia in the *Hi* group reported herein might be
218 due to the small sample size. Further, most cases of pneumonia in the *Hi* group occurred
219 more than 5 years after colonization, and *P. aeruginosa* was detected in the sputum of
220 two-thirds of the patients who developed pneumonia; thus, microbial substitution by
221 *P. aeruginosa* was possibly related to the incidence of pneumonia in the *Hi* group.

222 Reportedly, *P. aeruginosa* and *H. influenzae* are the most frequent colonizers of
223 the LRT in patients with non-CF bronchiectasis [12, 13]. They were also the major
224 colonizers and were isolated in cases of bronchiectasis in patients with RA in our study.
225 *S. aureus* colonization with bronchiectasis is associated with CF or allergic
226 bronchopulmonary aspergillosis [13, 14], although neither was seen in our patients.

227 The present study has several limitations. First, this study was a retrospective
228 study, and the sample size was small. The history of pneumococcal vaccination was
229 unavailable in the medical records, which might have affected the incidence of
230 pneumonia. Second, the detected microorganisms did not reflect the information of the
231 entire LRT. Furthermore, the conventional culture method has a limit when detecting

232 bacteria, and anaerobic bacteria may have been underestimated [15]. Third, only one
 233 point was assessed, and it is unclear if microbial substitution occurred after
 234 bronchoscopy. To accurately understand the effect of airway microbes on pneumonia in
 235 patients with RA, prospective studies with larger samples are required in the future.

236 **Conclusions**

237 In patients with RA, *P. aeruginosa*, *S. aureus*, and *H. influenzae* were the three
 238 major microbes isolated from the LRT, and the incidence of pneumonia was higher in
 239 these patients compared to the control group. *P. aeruginosa* colonization was associated
 240 with subsequent pneumonia in patients with RA. Our findings may contribute to the
 241 management of patients with RA whose LRT is colonized by *P. aeruginosa* by limiting
 242 unnecessary GC use, encouraging pneumococcal vaccination, and selecting
 243 antimicrobials that affect *P. aeruginosa* in the empiric treatment of pneumonia.

244

245 **Acknowledgments**

246 None.

247

248 **References**

- 249 1. Wakabayashi A, Ishiguro T, Takaku Y, Miyahara Y, Kagiya N,
250 Takayanagi N. Clinical characteristics and prognostic factors of
251 pneumonia in patients with and without rheumatoid arthritis. *PLoS*
252 *One* 2018;13 8: e0201799.
- 253 2. Mohd Noor N, Mohd Shahrir MS, Shahid MS, Abdul Manap R, Shahizon Azura
254 AM, Azhar Shah S. Clinical and high resolution computed tomography
255 characteristics of patients with rheumatoid arthritis lung disease.
256 *Int J Rheum Dis* 2009;12 2: 136-44.
- 257 3. Mori S, Koga Y, Sugimoto M. Different risk factors between
258 interstitial lung disease and airway disease in rheumatoid arthritis.
259 *Respir Med* 2012;106 11: 1591-9.
- 260 4. De Soyza A, McDonnell MJ, Goeminne PC, Aliberti S, Lonni S, Davison
261 J et al. Bronchiectasis Rheumatoid Overlap Syndrome Is an Independent
262 Risk Factor for Mortality in Patients With Bronchiectasis. *Chest*
263 2017;151 6: 1247-54.
- 264 5. Finch S, McDonnell MJ, Abo-Leyah H, Aliberti S, Chalmers JD. A
265 Comprehensive Analysis of the Impact of *Pseudomonas*
266 *aeruginosa* Colonisation on Prognosis in Adult Bronchiectasis. *Annals*
267 *of the American Thoracic Society* 2015;12 11: 1602-11.
- 268 6. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO,
269 3rd et al. 2010 rheumatoid arthritis classification criteria: an
270 American College of Rheumatology/European League Against Rheumatism
271 collaborative initiative. *Ann Rheum Dis* 2010;69 9: 1580-8.
- 272 7. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency
273 of infection in patients with rheumatoid arthritis compared with
274 controls: a population-based study. *Arthritis Rheum* 2002;46 9:
275 2287-93.
- 276 8. Kadota J, Mukae H, Ishii H, Nagata T, Kaida H, Tomono K et al.
277 Long-term efficacy and safety of clarithromycin treatment in
278 patients with diffuse panbronchiolitis. *Respiratory Medicine*
279 2003;97 7: 844-50.
- 280 9. Rogers GB, Bruce KD, Martin ML, Burr LD, Serisier DJ. The effect of
281 long-term macrolide treatment on respiratory microbiota composition
282 in non-cystic fibrosis bronchiectasis: an analysis from the
283 randomised, double-blind, placebo-controlled BLESS trial. *The*
284 *Lancet Respiratory Medicine* 2014;2 12: 988-96.
- 285 10. Yoshikawa H, Komiya K, Umeki K, Kadota J-i. Long-Term Macrolide
286 Antibiotic Therapy May Prevent the Development of Pneumonia in the
287 Elderly. *Journal of Palliative Medicine* 2014;17 7: 749-50.

- 288 11. Cox MJ, Turek EM, Hennessy C, Mirza GK, James PL, Coleman M et al.
289 Longitudinal assessment of sputum microbiome by sequencing of the
290 16S rRNA gene in non-cystic fibrosis bronchiectasis patients. PLoS
291 One 2017;12 2: e0170622.
- 292 12. Dimakou K, Triantafyllidou C, Toumbis M, Tsikritsaki K, Malagari K,
293 Bakakos P. Non CF-bronchiectasis: Aetiologic approach, clinical,
294 radiological, microbiological and functional profile in 277 patients.
295 Respiratory Medicine 2016;116: 1-7.
- 296 13. Pasteur MC, Helliwell SM, Houghton SJ, Webb SC, Foweraker JE, Coulden
297 RA et al. An investigation into causative factors in patients with
298 bronchiectasis. Am J Respir Crit Care Med 2000;162 4 Pt 1: 1277-84.
- 299 14. Shah PL, Mawdsley S, Nash K, Cullinan P, Cole PJ, Wilson R.
300 Determinants of chronic infection with Staphylococcus aureus in
301 patients with bronchiectasis. Eur Respir J 1999;14 6: 1340-4.
- 302 15. Yamasaki K, Mukae H, Kawanami T, Fukuda K, Noguchi S, Akata K et al.
303 Possible role of anaerobes in the pathogenesis of nontuberculous
304 mycobacterial infection. Respiriology 2015;20 5: 758-65.
305

228 patients with RA underwent
bronchoscopy

Excluded: (n = 107)

- Active infection (n = 71)
- Malignancy (n = 33)
- Tracheotomy (n = 1)
- Immunosuppressive therapy after
solid organ transplantation (n = 1)
- No available data (n = 1)

121 patients were enrolled

(A)

--- *P. aeruginosa*
— Control

Number of patients at risk:

Time, years	0	2	4	6	8
<i>P. aeruginosa</i>	16	14	10	6	3
Control	84	61	38	15	10

(B)

--- *S. aureus*
— Control

Number of patients at risk:

Time, years	0	2	4	6	8
<i>S. aureus</i>	15	9	7	3	1
Control	84	61	38	15	10

(C)

--- *H. influenzae*
— Control

Number of patients at risk:

Time, years	0	2	4	6	8
<i>H. influenzae</i>	6	5	4	3	1
Control	84	61	38	15	10